Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00WZK
|
|||
| Former ID |
DIB006515
|
|||
| Drug Name |
BC-3781 intravenous
|
|||
| Synonyms |
BC-3781 (intravenous), Nabriva; BC-3781 (oral), Nabriva
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Bacterial infection [ICD-11: 1A00-1C4Z; ICD-10: A00-B99] | Phase 2 | [1] | |
| Company |
Nabriva therapeutics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C28H45NO5S
|
|||
| Canonical SMILES |
CC1CCC23CCC(=O)C2C1(C(CC(C(C3C)O)(C)C=C)OC(=O)CSC4CCC(CC4O)N)C
|
|||
| InChI |
1S/C28H45NO5S/c1-6-26(4)14-22(34-23(32)15-35-21-8-7-18(29)13-20(21)31)27(5)16(2)9-11-28(17(3)25(26)33)12-10-19(30)24(27)28/h6,16-18,20-22,24-25,31,33H,1,7-15,29H2,2-5H3/t16-,17+,18?,20?,21?,22-,24+,25+,26-,27+,28+/m1/s1
|
|||
| InChIKey |
KPVIXBKIJXZQJX-IJUBVZAWSA-N
|
|||
| CAS Number |
CAS 1061872-97-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Bacterial Protein synthesis (Bact PROS) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01119105) Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI). U.S. National Institutes of Health. | |||
| REF 2 | Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010. Antimicrob Agents Chemother. 2013 Sep;57(9):4489-95. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.